The Atrial Fibrillation Devices Market will reach Expand Almost 4X at a CAGR of 13% between 2020 to 2030. Analytics and big data process unstructured as well as the structured biomedical structure and medical data for generating new-fangled insights. As such, digital therapy experiences get an enhanced look with MR (mixed reality), AR (augmented reality), and VR (virtual reality). This would be the trend regarding the healthcare vertical in the forecast period.
Interventional electrophysiology devices have already had a significant impact on patients suffering from cardiac arrhythmias, and are being increasingly adopted as a permanent treatment option for atrial fibrillation. Procedures such as radiofrequency ablation, cryoablation, and cox-maze are well performed in today’s practice.
Recent studies have found cryoablation to be more effective than medical management, and it is widely used in medical surgical practice. The overall market is primarily driven by the growing prevalence of atrial fibrillation amongst the geriatric as well as adult population, and the adoption of minimally-invasive techniques for the permanent treatment of atrial fibrillation.
Moreover, the use of innovative techniques, advancements in technology, and favorable reimbursement scenario are some other factors responsible for propelling the growth of the atrial fibrillation devices market.
Planning Forward? Access Sample Of Atrial Fibrillation Devices Market Report! https://www.persistencemarketresearch.co/samples/31531
Companies covered in Atrial Fibrillation Devices Market Report
- Biosensense Webster, Inc. (Johnson & Johnson)
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corporation
- AtriCure, Inc.
- Japan Lifeline Co.
- Biotronik, Inc
- MicroPort Scientific Corporation
- Biomerics
- CathRx
As such, the global atrial fibrillation devices market is estimated to be valued at US$ 3.9 Bn in 2020, with the market expected to exhibit a healthy CAGR of more than 14% during the forecast period (2020-2030).
Key Takeaways from Atrial Fibrillation Devices Market Study
- The diagnostics segment, by product, is expected to gain maximum revenue share over the forecast period. The therapeutic segment is anticipated to increase at a CAGR of 15% over 2020–2030, to reach US$ 8.3 Bn by 2030.
- According to PMR data collected from electrophysiologists in various regions, radiofrequency catheter ablation is the procedure of choice due to the high success rate, while cryoablation is the second preference for atrial fibrillation catheter ablation.
- By technology, the radiofrequency and cryoablation segments, collectively held more than 70% market share in terms of revenue in 2019.
- Among all end users, hospitals is the leading segment, which is followed by cardiac catheterization laboratories. The hospitals segment is anticipated to expand at a CAGR of 14% over the forecast period.
- North America and Europe, collectively held more than 70% revenue share in 2019, while South Asia is expected to show greater growth potential over the forecast period.
- With the ongoing Covid-19 pandemic wreaking havoc across the world, other non-emergency treatments have been deprioritized. As such in the near-term, the growth of the atrial fibrillation devices market will be slower than the average for the decade ahead.
“New product approvals and launches of ablation catheters along with increasing demand for minimally-invasive procedures offering increased longevity and safety profiles are driving the growth of the global atrial fibrillation devices market,” says a PMR analyst.
Planning To Introduce An Offbeat Product/Technology In The Atrial Fibrillation Devices Market? Go To “Purchase Now” To Have Our Atrial Fibrillation Devices Market Report! https://www.persistencemarketresearch.com/checkout/31531
Atrial Fibrillation Devices Market: Competition Landscape
The global market is set to broaden its scope during the forecast period, stimulated by the rising prevalence of AF, worldwide. In addition, a favorable reimbursement scenario and increasing demand for minimally-invasive procedures have augmented the sales of atrial fibrillation devices.
The market is dominated by 4 major manufacturers – Biosense Webster, Inc. (Johnson & Johnson), Abbott Laboratories, Medtronic Plc, and Boston Scientific Corporation, with a revenue share of over 70% in 2019. These major manufacturers are focusing on manufacturing electrophysiology devices used specifically for atrial fibrillation procedure, such as ablation devices, intracardiac echocardiography catheters, and left atrial appendage (LAA) management devices.
About us:
Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.
Contact us:
Persistence Market Research
305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com